The estimated Net Worth of Joana Goncalves is at least $4.69 Million dollars as of 5 April 2024. Joana Goncalves owns over 2,753 units of Cara Therapeutics Inc stock worth over $15,476 and over the last 6 years he sold CARA stock worth over $942,147. In addition, he makes $3,736,190 as Chief Medical Officer at Cara Therapeutics Inc.
Joana has made over 27 trades of the Cara Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 2,753 units of CARA stock worth $2,285 on 5 April 2024.
The largest trade he's ever made was selling 10,627 units of Cara Therapeutics Inc stock on 10 June 2020 worth over $161,530. On average, Joana trades about 2,261 units every 40 days since 2018. As of 5 April 2024 he still owns at least 53,365 units of Cara Therapeutics Inc stock.
You can see the complete history of Joana Goncalves stock trades at the bottom of the page.
DR. Joana Goncalves M.D. serves as Chief Medical Officer of the Company. Prior to joining Cara, Dr. Goncalves worked at Celgene Corporation from April 2014 to October 2018, where she most recently served as Vice President, Medical Affairs for Dermatology and Neurology and was instrumental in planning and executing medical support activities for a number of programs, including OTEZLA® for psoriasis. Previously, Dr. Goncalves held the position of Vice President, Medical Strategy and Scientific Affairs at LEO Pharma Inc., the U.S. subsidiary of LEO Pharma A/S, a global healthcare company specializing in dermatology and critical care, from February 2012 to April 2014. She began her pharmaceutical career at Novartis Pharmaceuticals, working on a range of products across various therapeutic areas from 2001 to 2012. Dr. Goncalves received her M.D. from the University of Cape Town, South Africa.
As the Chief Medical Officer of Cara Therapeutics Inc, the total compensation of Joana Goncalves at Cara Therapeutics Inc is $3,736,190. There are no executives at Cara Therapeutics Inc getting paid more.
Joana Goncalves is 46, he's been the Chief Medical Officer of Cara Therapeutics Inc since 2018. There are 18 older and no younger executives at Cara Therapeutics Inc. The oldest executive at Cara Therapeutics Inc is Harrison Bains, 76, who is the Independent Director.
Joana's mailing address filed with the SEC is C/O CARA THERAPEUTICS, INC., 400 ATLANTIC STREET, SUITE 500, STAMFORD, CT, 06901.
Over the last 11 years, insiders at Cara Therapeutics Inc have traded over $25,200,591 worth of Cara Therapeutics Inc stock and bought 1,874,453 units worth $19,406,983 . The most active insiders traders include Edward Hurwitz, Martin Vogelbaum, and Ventures Vi Lprmv Vi, L.L.C.... On average, Cara Therapeutics Inc executives and independent directors trade stock every 19 days with the average trade being worth of $5,343. The most recent stock trade was executed by Christopher Posner on 1 August 2024, trading 4,149 units of CARA stock currently worth $1,452.
cara therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat pain, inflammation and pruritus. cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. cara's most advanced patented compound, cr845, is currently undergoing clinical testing for acute pain and uremic pruritus. this compound possesses analgesic, anti-inflammatory and antipruritic activities appropriate for multiple therapeutic applications. in addition, cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology.
Cara Therapeutics Inc executives and other stock owners filed with the SEC include: